Effects of Midazolam on the Differentiation of Murine Myeloid Leukemia Cells

Mak, Nai Ki; Szeto, Y.Y.; Fung, Ming Chiu; Leung, Kwok Nam; Kwan, Stanley

doi:10.1159/000239578

Cited by 6 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This cell line has been widely used to be a useful model in the study of hematopoietic cell differentiation [2–4, 32, 33]. In the present study, we have demonstrated that rSj16 could induce macrophage differentiation of the WEHI-3B JCS cell (Figures 3–5).…”

Section: Discussionsupporting

confidence: 65%

Anti-Inflammatory Protein ofSchistosoma japonicumDirects the Differentiation of the WEHI-3B JCS Cells and Mouse Bone Marrow Cells to Macrophages

Mak

et al. 2010

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Sj16 is an anti-inflammatory protein identified from Schistosoma japonicum. Our previous studies showed that recombinant Sj16 (rSj16) could suppress host's inflammatory responses and inhibit macrophage maturation. In the present study, the effects of rSj16 on the differentiation of the murine myeloid leukemia WEHI-3B JCS cell line and on mouse hematopoiesis were investigated. Our data demonstrated that rSj16 expressed and purified from Escherichia coli could suppress the proliferation of the WEHI-3B JCS cells in a time- and concentration-dependent manner, while not affect the viability of the cells. Further studies indicated that rSj16 induced macrophage differentiation of the WEHI-3B JCS cells, and arrested the cell cycle in the G1/G0 and G2/M phases. The macrophage differentiation of the rSj16-treated WEHI-3B JCS cells was confirmed by their expression of macrophage specific antigen F4/80 and phagocytic activity. Furthermore, our results revealed that rSj16 biased the colony formation of mouse bone marrow cells towards macrophage linage.

show abstract

Section: Discussionsupporting

confidence: 65%

Anti-Inflammatory Protein ofSchistosoma japonicumDirects the Differentiation of the WEHI-3B JCS Cells and Mouse Bone Marrow Cells to Macrophages

Mak

et al. 2010

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Midazolam has been shown to inhibit the in vitro growth and differentiation of two murine myeloid leukemia cell lines (WEHI 3B (JCS) and M1 cells) in a dose-dependent manner [28]. Midazolam enhanced the expression of the differentiation antigens Mac-1, F4/80, and Gr-1 in the cells and expression of tumor necrosis factor (TNF-alpha), and the neutrophil-specific J11d differentiation marker was significantly upregulated in midazolam-treated JCS cells.…”

Section: Resultsmentioning

confidence: 99%

Insights into the Roles of Midazolam in Cancer Therapy

Jiao

Wang

Sun

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

With its high worldwide mortality and morbidity, cancer has gained increasing attention and novel anticancer drugs have become the focus for cancer research. Recently, studies have shown that most anesthetic agents can influence the activity of tumor cells. Midazolam is a γ-aminobutyric acid A (GABAA) receptor agonist, used widely for preoperative sedation and as an adjuvant during neuraxial blockade. Some studies have indicated the potential for midazolam as a novel therapeutic cancer drug; however, the mechanism by which midazolam affects cancer cells needs to be clarified. This systematic review aims to summarize the progress in assessing the molecular mechanism of midazolam as an anticancer agent.

show abstract